KAILERA THERAPEUTICS ($KLRA) posted quarterly earnings results for Q2 2026 on Wednesday, August 12th. The company reported earnings of -$1.09 per share, missing estimates of -$0.77 by $0.33. The company also reported revenue of $0, equaling estimates of $0 by $0.
Stock price change since market close: -2.1%
You can see Quiver Quantitative's $KLRA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
KAILERA THERAPEUTICS Insider Trading Activity
KAILERA THERAPEUTICS insiders have traded $KLRA stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $KLRA stock by insiders over the last 6 months:
- CAPITAL INVESTORS LLC BAIN purchased 8,398,438 shares for an estimated $134,375,008
- ANDREW T. KAPLAN purchased 8,398,438 shares for an estimated $134,375,008
- ADAM KOPPEL purchased 1,562,500 shares for an estimated $25,000,000
- CAPITAL LIFE SCIENCES INVESTORS, LLC BAIN purchased 1,562,500 shares for an estimated $25,000,000
- INVESTMENTS, LP RTW purchased 500,000 shares for an estimated $8,000,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
KAILERA THERAPEUTICS Hedge Fund Activity
We have seen 32 institutional investors add shares of KAILERA THERAPEUTICS stock to their portfolio, and 0 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 3,928,604 shares (+inf%) to their portfolio in Q2 2026, for an estimated $86,547,146
- GEODE CAPITAL MANAGEMENT, LLC added 1,133,115 shares (+inf%) to their portfolio in Q2 2026, for an estimated $24,962,523
- FEDERATED HERMES, INC. added 434,069 shares (+inf%) to their portfolio in Q2 2026, for an estimated $9,562,540
- TD ASSET MANAGEMENT INC added 147,698 shares (+inf%) to their portfolio in Q2 2026, for an estimated $3,253,786
- ABERDEEN GROUP PLC added 140,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $3,084,200
- BANK OF NEW YORK MELLON CORP added 138,399 shares (+inf%) to their portfolio in Q2 2026, for an estimated $3,048,929
- ALPS ADVISORS INC added 131,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $2,885,930
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
KAILERA THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $KLRA in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Evercore ISI Group issued a "Outperform" rating on 05/12/2026
To track analyst ratings and price targets for KAILERA THERAPEUTICS, check out Quiver Quantitative's $KLRA forecast page.
KAILERA THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $KLRA recently. We have seen 3 analysts offer price targets for $KLRA in the last 6 months, with a median target of $36.0.
Here are some recent targets:
- Hardik Parikh from JP Morgan set a target price of $30.0 on 05/12/2026
- David Risinger from Leerink Partners set a target price of $36.0 on 05/12/2026
- Roger Song from Jefferies set a target price of $48.0 on 05/12/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
